Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.03M | 7.01M | 6.21M | 5.17M | 4.50M | 2.48M |
Gross Profit | 1.51M | 1.51M | 1.81M | 1.12M | 754.00K | 83.00K |
EBITDA | -37.24M | -33.22M | -20.91M | -18.52M | -14.55M | -10.23M |
Net Income | -36.14M | -32.01M | -19.92M | -18.49M | -14.92M | -10.54M |
Balance Sheet | ||||||
Total Assets | 38.67M | 46.81M | 47.64M | 24.65M | 39.71M | 17.78M |
Cash, Cash Equivalents and Short-Term Investments | 26.09M | 34.64M | 39.02M | 17.80M | 34.04M | 12.64M |
Total Debt | 1.64M | 2.34M | 1.59M | 1.61M | 1.20M | 999.00K |
Total Liabilities | 2.96M | 10.72M | 8.14M | 7.26M | 6.18M | 5.61M |
Stockholders Equity | 28.34M | 36.09M | 39.50M | 17.39M | 33.53M | 12.16M |
Cash Flow | ||||||
Free Cash Flow | -27.16M | -23.27M | -16.76M | -16.02M | -13.55M | -9.17M |
Operating Cash Flow | -25.60M | -21.87M | -16.38M | -15.54M | -13.21M | -9.08M |
Investing Cash Flow | 9.53M | 12.64M | -16.09M | 8.44M | -22.46M | -187.00K |
Financing Cash Flow | 18.96M | 18.45M | 37.53M | -140.00K | 35.03M | 16.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $75.48M | 41.95 | 3.46% | ― | 24.75% | -61.29% | |
59 Neutral | HK$15.37B | 5.76 | -7.44% | 4.08% | 11.55% | -28.15% | |
52 Neutral | $59.55M | ― | -67.86% | ― | 0.34% | 6.20% | |
50 Neutral | $68.01M | ― | -113.95% | ― | 8.49% | 6.09% | |
47 Neutral | $59.40M | ― | -173.47% | ― | 0.34% | 9.38% | |
46 Neutral | $64.49M | ― | -94.65% | ― | -5.86% | 50.76% | |
44 Neutral | $75.24M | ― | -117.76% | ― | ― | 15.22% |
On July 9, 2025, InspireMD announced the U.S. commercial launch of its CGuard® Prime Carotid Stent System, following FDA premarket application approval. This launch represents a significant milestone for InspireMD, which has already captured a double-digit market share in over 30 countries. The CGuard Prime is designed to enhance embolic protection and improve patient safety in stroke prevention, featuring a dual-layer design and SmartFit™ technology. The launch is expected to strengthen InspireMD’s position in the U.S. market, supported by a seasoned commercial team and robust operational infrastructure.
The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.
On June 23, 2025, InspireMD announced that the FDA granted premarket approval for its CGuard Prime Carotid Stent System in the United States, marking a significant milestone for the company. The approval, supported by the C-GUARDIANS pivotal trial, positions InspireMD to launch the stent system in the U.S. market, potentially impacting the carotid stenting industry by offering a less invasive treatment option for carotid artery disease.
The most recent analyst rating on (NSPR) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.
On June 13, 2025, InspireMD announced it received CE Mark approval under the European Medical Device Regulation (MDR) for its CGuard® Prime Embolic Prevention System (EPS), a significant milestone for the company. This approval allows for the commercial launch of CGuard® Prime EPS in European markets, enhancing InspireMD’s position in carotid stenting innovation and paving the way for a potential U.S. launch pending FDA approval, thereby expanding its market reach and operational scale.
The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.
On June 3, 2025, InspireMD, Inc. conducted its annual meeting of stockholders, where 66.84% of the shares were represented, constituting a quorum. During the meeting, stockholders re-elected Michael Berman and Scott R. Ward as Class 2 directors for a three-year term and ratified Kesselman & Kesselman as the independent auditors for the 2025 fiscal year.
The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.
On June 3, 2025, InspireMD announced the appointment of Michael Lawless as Chief Financial Officer, effective by June 30, 2025. Lawless, who brings extensive financial leadership experience from the healthcare sector, will replace Craig Shore, who has been with the company for nearly 15 years. This leadership change comes as InspireMD prepares for the U.S. launch of its CGuard Prime system, marking a significant phase in its commercial expansion. In connection with his appointment, Lawless will receive an inducement grant of restricted stock and stock options, which will vest over three years, aligning with Nasdaq Listing Rule 5635(c)(4).
The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.